Overexpression of miR-21 Is Associated With Recurrence in Patients With Hepatitis B Virus-Mediated Hepatocellular Carcinoma Undergoing Liver Transplantation

No Thumbnail Available

Date

2019-05

Authors

Journal Title

Journal ISSN

Volume Title

Publisher

Elsevier

Abstract

Liver transplantation (LT) is the best treatment option for hepatitis B virus (HBV)e mediated hepatocellular carcinoma (HCC). Nevertheless, recurrence is the most important issue after LT. The aims of the present study were to evaluate the relation of dysregulated expression of microRNAs (miRNAs) in recurrence formation in HBV-mediated HCC cases. A total of 42 HBV-mediated HCC patients were evaluated in this study. Among 21 miRNAs, the expression level of miR-106a and miR-21 were higher and miR-143 and miR145 were lower in patients with HCC compared with noncancerous liver tissues (P = .0388, P = .0214, P = .0321, and P = .002, respectively). Compared with nonrecurrent patients, the expression level of miR-21 was 3.54-fold higher and miR-145 was 2.42-fold lower in patients with recurrence during the 5-year follow-up (P = .004 and P = .032; respectively). In addition, according to multivariate Cox regression analysis, the overexpression of miR-21 was found to be a prognostic indicator in HBV-mediated HCC patients (P = .002). In conclusion, we show a significant association between high expression of miR-21 and recurrence in HBV-mediated HCC. Therefore, up-regulation of miR-21 could serve as a promising prognostic marker for HCC.

Description

Bu çalışma, 18-21 Ekim 2018 tarihleri arasında Trabzon[Türkiye]’da düzenlenen 12. Congress of the Turkish-Transplantation-Centers-Coordination-Association (TTCCA)’da bildiri olarak sunulmuştur.

Keywords

Immunology, Surgery, Transplantation, Micrornas, Biomarkers, Expression, Prognosis, Diagnosis

Citation

Dündar, H. Z. vd. (2019). ''Overexpression of miR-21 Is Associated With Recurrence in Patients With Hepatitis B Virus-Mediated Hepatocellular Carcinoma Undergoing Liver Transplantation''. Transplantation Proceedings, 51(4), 1157-1161.